No PFS Benefit With Carotuximab in Advanced Angiosarcoma
Researchers compared carotuximab plus pazopanib with pazopanib alone in patients with advanced angiosarcoma.
Researchers compared carotuximab plus pazopanib with pazopanib alone in patients with advanced angiosarcoma.
Fyarro has also been added to the NCCN Guidelines as the only preferred treatment regimen for malignant PEComa.
Crossover randomized study sought to determine if structured journaling could lead to improved quality of life, symptom management, and communication with the clinical care team.
Young adults were more likely to receive chemotherapy.
Adding temozolomide to vincristine and irinotecan improved survival.
CMB305 increased antibody responses and NY-ESO-1-specific T-cell responses.
Nab-sirolimus is an mTOR inhibitor bound to human albumin.
A facility in northwest Montana shares its experiences with developing a brachytherapy service and expanding it to include treatment of soft tissue sarcoma.
Radioresistant sarcoma may require treatment intensification.
Compared with patients who undergo surgery alone for abdominal or pelvic cancers, those who receive radiation and chemotherapy are at elevated risk for secondary sarcomas.